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Background. Benign Prostatic Hyperplasia (BPH) is a benign tumor that most often occurs 
in men. Many risk factors could cause BPH, one of which is diabetes mellitus (DM). 
Diabetes mellitus (DM) is a metabolic disease, characterized by hyperglycemia.  
Method. This study was conducted at the Urology Polyclinic of the Universitas  Sumatera 
Utara Hospital from August to September 2019. A total of 102 patients diagnosed with 
BPH were registered by cross-sectional study approach. Detailed medical history and 
physical examination were performed for all patients to diagnose BPH. While the diagnosis 
of DM was according to patient history or diabetic-medicine use. International Prostate 
Symptom Score (IPSS) were completed by all patients to obtain a LUTS degree. 
Result. From a total of 102 patients diagnosed with BPH there were 97 patients were 
selected. The mean age of patients was 70.43 ± 7.52 year (range 50-88 year) and the total 
IPSS score was 17.55 ± 6.55. DM patients were more likely to report severe LUTS and the 
symptom score evaluated with IPSS was significantly higher than in non non-DM group: 
21.69 ± 5.41 vs 16.70 ± 6.41 (p=0.005). For the IPSS subscores, the DM group also show 
higher storage: 8.38 ± 4.57 vs 5.88 ± 3.72 (p = 0.02), voiding: 9.69 ± 2.47 vs 8.14 ± 3.21, 
(p= 0.039) and post micturition: 3.63 ± 1.26 vs 2.69 ± 1.744, (p= 0.045) symptoms 
significantly.  
Conclusion: Benign Prostatic Hyperplasia patients with DM manifested more severe lower 
urinary tract symptoms. Storage, voiding, post micturition, and urgency symptoms were 
also greater.  
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ABSTRAK. 
Latar belakang. Benign Prostatic Hyperplasia (BPH) adalah tumor jinak yang paling sering 
terjadi pada pria. Banyak faktor risiko yang dapat menyebabkan BPH, salah satunya adalah 
diabetes mellitus  (DM). Diabetes mellitus (DM) adalah penyakit metabolik, ditandai dengan 
hiperglikemia.  
Metode. Penelitian ini dilakukan di Poliklinik Urologi Rumah Sakit Universitas Sumatera 
Utara dari Agustus hingga September 2019. Sebanyak 102 pasien yang didiagnosis dengan 
BPH terdaftar dengan pendekatan studi potong lintang. Dirinci riwayat medis dan dilakukan 
pemeriksaan fisik untuk semua pasien untuk mendiagnosis BPH. Sedangkan diagnosis DM 
sesuai riwayat pasien atau penggunaan obat diabetes. Dilakukan pemeriksaan International 
Prostate Symptom Score (IPSS) pada semua pasien untuk mendiagnosa LUTS. 
Hasil. Dari  total 102 pasien yang didiagnosis dengan BPH, ada  97 pasien yang dipilih. 
Usia pasien adalah 70,43 ± 7,52  tahun (kisaran 50-88  tahun) dan total skor IPSS adalah 
17,55 ± 6,55. Pasien DM lebih melaporkan LUTS berat dan evaluasi skor gejala dengan 
IPSS secara signifikan lebih tinggi daripada pada kelompok non-DM: 21,69 ± 5,41 vs 16,70 
± 6,41 (p = 0,005). Grup DM juga lebih tinggi secara signifikan pada IPSS skor: 8,38 ± 4,57 
vs 5,88 ± 3,72 (p = 0,02), berkemih: 9,69 ± 2,47 vs 8,14 ± 3,21, (p = 0,039) dan setelah 
berkemih: 3.63 ± 1,26 vs 2,69 ± 1.744, (p = 0,045). 
Kesimpulan:  Pasien BPH dengan DM manifestasi gejala saluran kemih bagian bawah lebih 
berat. Menahan berkemih, berkemih, setelah berkemih, dan gejala urgensi juga lebih besar.  
 
Kata kunci: BPH, DM, IPSS, derajat LUTS  
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1 Introduction 
Benign Prostatic Hyperplasia (BPH) is a histologic diagnosis that refers to the proliferation of 
smooth muscle and epithelial cells within the prostatic transition zone.[1] It is the most common 
benign tumor found in men.[2] The incidence of BPH is depended on age. BPH results in 
compression of the urethra, causing resistance to urine flow known as bladder outlet obstruction 
(BOO). This resistance can also result in changes in bladder function, such as overactivity of the 
detrusor muscle or, conversely, reduced contractility of the detrusor muscle that is known as 
Lower Urinary Tract Symptoms (LUTS).[3] 
The International Continence Society has divided LUTS into three categories, voiding, storage, 
and post micturition. Voiding symptoms correspond to urinary hesitancy, straining, intermittency, 
weak urinary stream, and dysuria. Storage symptoms correspond to urinary frequency, nocturia, 
and urgency with or without incontinence. Post micturition symptoms correspond to the sensation 
of incomplete voiding, and/or post micturition dribbling.[4,5] A guideline to direct those 
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symptoms due to prostate enlargement is the complaint scoring system, known as the International 
Prostate Symptoms Score (IPSS) questionnaire.[6] 
BPH and diabetes have significant overlap in voiding dysfunction symptoms, but evidence also 
exists that diabetes promotes the disease process of BPH. Disruptions in glucose homeostasis at 
multiple different levels—from alterations in serum insulin growth factor concentrations to 
diagnosis of clinical diabetes—are associated with higher likelihoods of prostate enlargement, 
BPH, and LUTS.[7,8] In the Baltimore Longitudinal Study of Aging, Parsons et al. noted that 
men with diabetes were more likely to have LUTS three times than men without diabetes.[9] 
Fasting insulin plasma also is an independent risk factor of prostatic gland volume. Diabetes could 
double moderate-severe LUTS risk.[10] The objective of this research is to compare the degree 
of LUTS in benign prostatic hyperplasia patients with and without diabetes mellitus based on the 
IPSS score. 
2 Method 
This study was conducted at the Urology Polyclinic of the Universitas  Sumatera Utara Hospital 
from August to September 2019. A total of 102 patients diagnosed with Benign Prostatic 
Hyperplasia were registered by cross-sectional study approach with a total sampling technique. 
Then 97 patients were selected due to exclusion criteria which were neurologic bladder 
dysfunction, bladder stones, and urinary tract infection. Among those 97 patients, 81 patients did 
not have DM and 16 patients had DM.  
Detailed medical history and physical examination were performed for all patients to diagnose 
BPH. While the diagnosis of DM was according to patient history or diabetic-medicine use. 
International Prostate Symptom Score (IPSS) were completed by all patients to obtain a LUTS 
degree.  
Statistical analysis 
Statistical analysis was done by using SPSS 24.0 (SPSS Inc., Chicago, IL, USA). All data are 
statically described in terms of mean ± standard deviation (SD) and frequencies. We divided the 
population into two groups: patients with and without DM group. The total IPSS score, storage 
score, voiding score, post micturition, and their subscores were compared between the two groups 
by independent sample t-test with normal-data-distribution assumptions (Kolmogorov-Smirnov, 
P > 0.05). The assumptions that did not meet would be replaced by Levene's test. Differences 
resulting in a P< 0.05 in equal variances assume row were considered statistically significant if 
Levene's test was above 0.05 and vice versa. 
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3 Results 
In table 1, shows that the mean age of 97 patients was 70.43 ± 7.52 (range 50-88) and the total 
IPSS score was 17.55 ± 6.55.  
Table 1 Patient Characteristics 
Variables Mean ± SD 
Number of patients 97 
Age (year) 70.43 ± 7.521 
Total IPSS 17.55 ± 6.55 
  
 
In table 2, DM patients were more likely to report severe LUTS and the symptom score evaluated 
with IPSS was significantly higher than in non non-DM group: 21.69 ± 5.41 vs 16.70 ± 6.41 
(p=0.005). For the IPSS subscores, the DM group also show higher storage: 8.38 ± 4.57 vs 5.88 
± 3.72 (p = 0.02), voiding: 9.69 ± 2.47 vs 8.14 ± 3.21, (p= 0.039) and post micturition: 3.63 ± 
1.26 vs 2.69 ± 1.744, (p= 0.045) symptoms significantly. Among the voiding symptoms, urgency 
score was higher in DM patients: 2 .88 ± 1.26 vs 1.81 ± 1.77 (p= 0.08). 
Table 2 Differences in IPSS questionnaire results between patients with and without 
DM group 
Variables DM Non-DM P value 
Number of patients 16 81  
IPSS score 21.69 ± 5.41 16.70 ± 3.72 0.005* 
Storage 8.38 ± 4.573 5.88 ± 3.72 0.020* 
Q3 2.88 ± 1.59 2.04 ± 1.64 0.063* 
Q5 3.00 ± 1.71 2.16 ± 1.61 0.062* 
Q6 2.50 ± 1.67 1.68 ± 1.71 0.081* 
Voiding 9.69 ± 2.47 8.14 ± 3.21 0.039* 
Q2 3.56 ± 1.41 3.10 ± 1.38 0.223* 
Q4 2.88 ± 1.26 1.81 ± 1.78 0.008* 
Q7 3.25 ± 1.13 3.22 ± 1.20 0.932* 
Post micturition or 
3.63 ± 1.26 2.69 ± 1.74 0.045* 
Q1 
Q1 = incomplete emptying; Q2 = frequency; Q3 = intermittency; Q4 = urgency with or 
without incontinence; Q5 = weak-steam; Q6 = straining; Q7 = nocturia; *P value<0,050 
4 Discussion 
BPH is believed to cause LUTS through a dynamic component of increased smooth muscle tone 
mediated by α-1 adrenergic receptors as well as a static component of BOO due to the mass of 
the prostate.[6] While diabetes could be explained by multiple pathways. First, hyperinsulinemia 
is associated with increased sympathetic nerve activity. The second, dysregulation of the insulin-
like growth factor (IGF). IGF has similarity structure in prostate cells. Insulin combines with to 
IGF receptor enters prostate cells, causing receptor activation to induce growth and proliferation. 
Third, insulin may increase the transcription of genes/ translation of proteins involved in sex 
hormone metabolism influencing the prostatic hormonal milieu.[9-11]  
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In this study, DM patients clearly show differences in LUTS symptoms. Similarly, a study by 
Ozcan et al results in a significantly higher total IPSS score in patients with DM.[12] Bang et al. 
analyzed an association between DM and increased prostate volume indicating that DM is an 
important factor for a static component of BPH/LUTS.[13] The total IPSS, storage symptom, and 
post micturition symptom scores are significantly higher in the DM group. While voiding 
symptoms did not show significant differences. Among storage symptoms, frequency and 
nocturia also showed significant differences. On the contrary, we found significant differences in 
voiding and its urgency symptom. Initial osmotic diuresis induced by hyperglycemia causes 
bladder wall stretching, along with increased intravesical pressure results in compensated bladder 
hypertrophy. This would correspond clinically to storage symptoms at first. As the disease 
progresses, advanced glycation end products induce delirious changes. Oxidative stress releases 
toxic products that result in bladder decompensation.  Hyperinsulinemia is connected to 
sympathetic nerve activity that causes increasing in prostatic smooth muscle and bladder 
obstruction.[9-11] The obstruction causes bladder dysfunction-detrusor muscle instability-
clinically related to frequency and urgency. Along with those symptoms, trabeculation as a result 
of increased detrusor muscle collagen could cause an incomplete emptying sensation.[14]  
Limitations to this study were: sample size of the study was not equal, subjective answers might 
not be consistent with actual bladder dysfunction, and  how long a patient had DM. 
5 Conclusions 
Benign Prostatic Hyperplasia patients with DM manifested more severe lower urinary tract 
symptoms. Storage, voiding, post micturition, and urgency subscore symptoms were also greater 
but not in the other subscore symptoms.  
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